Albertsons Companies, Inc.

All tables below present one row per metric with fiscal years in chronological order. FY2021 = 52 weeks ended 26 February 2022; FY2022 = 52 weeks ended 25 February 2023; FY2023 = 52 weeks ended 24 February 2024; FY2024 = 52 weeks ended 22 February 2025; FY2025 = 53 weeks ended 28 February 2026.

Income statement

Unadjusted EBITDA is calculated as net income plus interest expense net, income tax expense and depreciation and amortisation; it is a dossier calculation, not a company-reported measure. Declared annual dividend per share is the annualised declared quarterly rate; cash dividends actually paid in each fiscal year differ because of payment timing (see cash flow table).

Margin analysis (percentages)

Revenue CAGR, FY2021 to FY2025: 3.7% reported. Adjusting FY2025 to remove the approximately $1,400 million contributed by the 53rd week, the underlying four-year CAGR is approximately 3.3%.

Cash flow

FY2021 and FY2024 remodel counts are approximate and derived from company commentary rather than a single disclosed table. No share repurchase programme was in place before 11 December 2024; nil entries for FY2021 to FY2023 reflect the absence of a programme, not an unavailability of data. Free cash flow is calculated as operating cash flow less capital expenditures and is a dossier calculation.

Ratios

Return on invested capital is calculated as operating income multiplied by one minus the effective tax rate, divided by year-end total debt plus total equity; it excludes operating lease liabilities and is therefore flattering relative to a lease-adjusted measure. Net debt to Adjusted EBITDA reproduces the company's own reported net debt ratio. Return on equity is calculated on year-end equity for consistency across all five years; because equity is small and highly volatile — swinging from $1,610.7 million to $3,385.9 million and back to $1,836.2 million within three years, largely on buybacks and special dividends — the ratio should be read as a leverage artefact rather than an operating signal.

Commentary on trends, inflections and drivers

Revenue. Top-line growth over the period is almost entirely inflation and pharmacy. Identical sales rose 6.9% in FY2022 on peak food inflation, then decelerated to 3.0%, 2.0% and 2.0%. In FY2025 management explicitly identifies pharmacy as "the primary driver of the identical sales increase," meaning the grocery core was close to flat on a like-for-like basis. Store count declined from 2,276 to 2,244 over five years, with 35 closures in FY2025 alone against nine openings — the largest net closure year in the period. The Q1 FY2026 identical-sales decline of 0.8% is the first negative print since FY2021 and marks a genuine inflection: management attributes it to "softer industry unit trends and a more cautious consumer," with revenue held flat only by higher fuel sales.

Gross margin. Gross margin rate has declined in each of the five years, from 28.8% to 27.2%, a 160 basis point erosion. The drivers are consistent and structural rather than cyclical: pharmacy mix, which carries materially lower gross margin rate and rose from 8.7% to roughly 13.9% of sales; and digital delivery and handling costs, cited in every recent quarter as the leading incremental drag. FY2025 saw a partial offset from improved pharmacy margins as IRA pricing dynamics reduced the cost side even as they suppressed revenue. Q1 FY2026 gross margin of 26.6% continues the trend, down 50 basis points year on year and 23 basis points excluding fuel and LIFO.

Operating leverage. Selling and administrative expenses were held at 25.2% of sales through FY2022 and FY2023 but have since risen to 25.6% and 26.3%. The FY2025 figure is distorted by the $773.8 million opioid charge; excluding fuel and the opioid charge, Q4 FY2025 SG&A rate was down two basis points, which management presents as evidence of cost discipline. The honest reading is that productivity has roughly offset wage and occupancy inflation but has not created positive leverage, and in Q1 FY2026 SG&A rate rose 42 basis points excluding fuel — driven by rent and occupancy, merger litigation costs, business transformation costs and depreciation — because the sales denominator went backwards.

Operating income and net income. The collapse is dramatic and partly optical. Operating income fell 70% from $2,436.9 million to $727.6 million over five years; net income fell 87% from $1,619.6 million to $217.4 million. Roughly $774 million of the FY2025 decline is the one-time opioid settlement charge. Stripping that out, adjusted operating income would be approximately $1,501 million, still a 38% decline from FY2021. Adjusted EBITDA, the metric management runs the business on, declined more gently — from $4,398.4 million to $3,901.5 million, or 11% over four years — and that gap between GAAP collapse and adjusted resilience is itself the central analytical question: cumulative adjustments have grown from $136 million in FY2021 to $992 million in FY2025 (excluding the tax effect), and merger-related costs alone have run at $56 million, $181 million, $255 million and $84 million in FY2022 through FY2025.

Balance sheet and leverage. The single most consequential balance-sheet event of the period was the January 2023 special dividend of $3,916.9 million, which took cash from $2,902.0 million to $455.8 million and equity from $3,024.6 million to $1,610.7 million in one year, permanently resetting the leverage profile. Net debt to Adjusted EBITDA has since risen from 1.15x to 2.24x at FY2025 year end and 2.33x at Q1 FY2026 — the increase in FY2025 being driven by both numerator (debt up $1,126.5 million to fund $1,492.5 million of buybacks) and denominator (Adjusted EBITDA down $103 million). Working capital is structurally negative, a normal and favourable characteristic for grocery, but the cash conversion cycle has deteriorated from 4.7 days to 11.1 days as payables days compressed from 30.2 to 24.2 — a quiet erosion of supplier float worth roughly $360 million of working capital over the period.

Cash generation. Operating cash flow has declined every year since FY2021, from $3,513.4 million to $2,366.7 million. Free cash flow after capex has been between $527 million and $749 million in each of the last four years, against FY2025 shareholder returns of $1,815 million (dividends plus buybacks). The company funded that gap with debt. This is sustainable only for as long as leverage headroom permits, and with FY2026 guidance implying Adjusted EBITDA of roughly $3.59 billion at the midpoint, net debt to Adjusted EBITDA moves toward 2.5x on unchanged returns — a level at which the pace of buybacks becomes a genuine board-level trade-off rather than a formality.

Management guidance

For fiscal 2026 (52 weeks ending 27 February 2027), management guides to identical sales of (1.5)% to (0.5)%, Adjusted EBITDA of $3.550 to $3.625 billion, adjusted net income per share of $1.75 to $1.85, an effective tax rate of 24% to 25%, and capital expenditures of $1.9 to $2.0 billion. The identical-sales range embeds an estimated 150 basis point headwind from the IRA Medicare Drug Price Negotiation Program. Beyond fiscal 2026, no medium-term financial targets have been published; the previous "2%+ identical sales with Adjusted EBITDA growth above identical sales" algorithm has been overtaken by events and not replaced.

The one quantified forward commitment outside guidance is the ACI Edge programme: approximately $200 million of incremental annual run-rate benefit, building through fiscal 2026 with the majority realised in fiscal 2027, against approximately $50 million of transition costs.

Consensus expectations

Nineteen analysts carry a consensus Hold rating with an average twelve-month target near $14.19. Q2 FY2026 consensus adjusted EPS is approximately $0.43, reporting on or about 13 October 2026. Sell-side targets have compressed from a $22 to $28 cluster pre-July to an $11 to $14 cluster today, with UBS and Citi both moving to Neutral at $12 and $11 respectively.

Bull case

1. The valuation already discounts a permanent impairment that may not be permanent. At approximately 6.8x guided FY2026 adjusted EPS, 4.2x EV to guided Adjusted EBITDA (excluding leases) and an 8.8% trailing free cash flow yield, the market is pricing continued decline. Albertsons has generated between $527 million and $749 million of free cash flow in each of the last four years through a merger collapse, a CEO transition and a pharmacy pricing shock. A stabilisation at flat identical sales — not a return to growth — would support a materially higher multiple.

2. ACI Edge plus retail media is a credible $300 million-plus profit bridge. The $200 million run-rate benefit alone is roughly 5.5% of guided FY2026 Adjusted EBITDA. Layered onto a retail media business that management identifies as the funding source for price investment, and that is now integrated into conversational AI search through Criteo, the company has an identifiable path to arresting margin decay without further price abdication. Whitman's appointment supplies the transformation credibility the board lacked.

3. Two large un-modelled assets sit off the income statement. The Kroger claim — a $600 million contractual fee plus damages for years of foregone strategic optionality — is worth up to 10% or more of the current market capitalisation, and Kroger has already settled the analogous C&S claim. Separately, 39% of a 112 million square foot estate is owned or ground-leased at historic cost, providing a deleveraging option the company has barely touched (asset sale proceeds were only $109.5 million in FY2025).

Bear case

1. The margin decline is structural, not cyclical, and management has no published plan to reverse it. Adjusted EBITDA margin has fallen every year for five years — 6.12%, 6.02%, 5.45%, 4.98%, 4.69% — and FY2026 guidance implies approximately 4.3%. The cause is mix: pharmacy grew from 8.7% to 13.9% of sales and digital grew 21%, and both are rate-dilutive by construction. Growing the growth engines makes the margin worse. The company abandoned its long-term algorithm without replacing it, which is a tacit admission that the bridge back does not currently exist.

2. Capital allocation has destroyed value at scale and constrains future flexibility. Albertsons repurchased 78.7 million shares for $1,492.5 million in FY2025 — including a $750 million ASR at an average $17.57 — while free cash flow was $527.3 million. The gap was debt-funded, taking net leverage from 1.88x to 2.33x. At $12.33, that FY2025 programme is marked down by roughly $500 million. With guided EBITDA falling to $3.59 billion, further buybacks push leverage toward 2.5x on a BB+ credit, at which point the board must choose between returns and the balance sheet.

3. Simultaneous leadership discontinuity at the worst possible moment. A CEO sixteen months into her first public-company chief executive role, a CFO who announced retirement on the day of a 22% share price collapse with no successor named, a newly created Executive Chair layered above the CEO, a merchandising organisation being rebuilt from eleven divisions into four regions, two securities investigations, a DOJ inquiry and an unresolved billion-dollar litigation — all at once. The base rate for turnarounds executed successfully under that combination of conditions is low, and ACI Edge's $200 million target requires precisely the organisational stability the company does not have.

Catalysts and monitorables, next twelve months

Analyst verdict

Albertsons today is a company whose asset base is materially better than its earnings trajectory, and whose earnings trajectory is materially worse than management represented four months ago. The core question for an investor is whether the FY2026 guidance cut marks a floor or a waypoint, and the honest answer from the disclosed data is that there is not yet enough evidence to say.

The bear framing is straightforward and difficult to dismiss. Five consecutive years of margin compression, driven by a mix shift the company is deliberately accelerating, is a structural problem rather than a cyclical one. Pharmacy and digital are the only meaningful growth vectors and both dilute rate; growing them faster makes the margin arithmetic worse, not better. Operating income has fallen 70% in five years and the gap between GAAP results and adjusted results has widened every year. Management withdrew its long-term algorithm without publishing a replacement, which is the clearest possible signal that the internal bridge from a 4.3% EBITDA margin back toward 5% is not yet built. Meanwhile the balance sheet has been levered up to fund buybacks executed at prices roughly 40% above the current quote — approximately half a billion dollars of realised value destruction that also consumed the flexibility now needed.

The bull framing is not that the business is good, but that the price already assumes it is bad. At roughly 4.2x EV to guided EBITDA and an 8.8% free cash flow yield, the equity is priced for continued erosion. Yet the company generated between $527 million and $749 million of free cash flow in each of the last four years, through a failed merger, a leadership transition, a pharmacy pricing shock and 35 store closures. The real estate is genuinely irreplaceable, the loyalty file of 51.2 million members is a real asset, and the $774 million opioid framework converts an open-ended liability into a scheduled obligation. ACI Edge's $200 million target is roughly 5.5% of guided EBITDA and does not require heroic assumptions. The Kroger claim is a free option worth up to a tenth of the market capitalisation.

The decisive variable is execution capacity, and this is where the assessment turns cautious. The Whitman appointment reads less as a strategic upgrade than as a board that has lost confidence in the current arrangement — an Executive Chair with an operations brief, installed six weeks after a 22% collapse, above a CEO of sixteen months, alongside a CFO seat that is vacant in all but name. The organisation is simultaneously being rebuilt from eleven divisions into four while centralising the merchandising function that determines in-stocks, assortment and supplier economics. That is a great deal of change to absorb while comparable sales are negative.

Verdict: Albertsons is a credible deep-value proposition with a genuinely asymmetric litigation option, wrapped around an operating business in structural margin decline and an organisation in simultaneous leadership and structural transition. The valuation compensates for the first risk but not obviously for the second. Two observable events would materially change the assessment: a Q2 identical-sales print at or above the top of guidance, and the appointment of a credible external CFO who rebases and defends a multi-year margin bridge. Until both occur, the appropriate stance is to treat the equity as a monitorable rather than a position, and to size any exposure to the possibility that fiscal 2026 guidance is cut a second time.

---

SOURCE AND VERIFICATION NOTES

• Financial statement data for FY2021 through FY2025 and Q1 FY2026 are taken directly from company earnings releases furnished on Form 8-K and from the FY2025 Form 10-K and Q1 FY2026 Form 10-Q.

• Derived metrics — unadjusted EBITDA, free cash flow, ROE, ROA, ROIC, current ratio, debt-to-equity, interest coverage, asset turnover, DIO, DSO, DPO and cash conversion cycle — are dossier calculations from disclosed inputs and are identified as such in the relevant sections.

• Share price, market capitalisation, analyst consensus and institutional ownership data are from market data providers and were current within approximately two weeks of the dossier date.

• Where sources conflict, both are noted. The most significant conflict encountered is analyst consensus price target, where one aggregator reported an average of $14.19 across 19 analysts while another displayed $20.25 across the same nominal panel; the lower figure is consistent with the post-July downgrades from UBS ($12) and Citi ($11) and is used throughout. A second conflict concerns Cerberus's ownership percentage, reported as approximately 27.6% by 13F aggregators calculating against a stale share count and as approximately 30% in the FY2025 Form 10-K; the filing figure should be preferred.